Halozyme Therapeutics, Inc. (NASDAQ:HALO) Halozyme to Acquire Elektrofi Conference Call October 1, 2025 8:30 AM EDT
Company Participants
Tram Bui – Head of Investor Relations & Corporate Communications
Helen Torley – President, CEO & Director
Conference Call Participants
Morgan Gryga – Morgan Stanley, Research Division
Brendan Smith – TD Cowen, Research Division
Michael DiFiore – Evercore ISI Institutional Equities, Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Jason Butler – Citizens JMP Securities, LLC, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
David Risinger – Leerink Partners LLC, Research Division
Presentation
Operator
Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme Investor Call. [Operator Instructions] Please note, this event is being recorded. I will now turn the call over to Tram Bui, Halozyme’s Vice President of Investor Relations and Corporate Communications. Please go ahead.
Tram Bui
Head of Investor Relations & Corporate Communications
Thank you, operator. Good morning, and welcome to our investor conference call. In addition to the press release issued earlier this morning, you could find a supplementary slide presentation that will be referenced during today’s call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme’s President and Chief Executive Officer, who will provide an overview of the transaction. We’re also pleased to have Chase Coffman, CEO and Co-Founder of Elektrofi, joining us today, together with Nicole LaBrosse, our CFO.
On today’s call, we will be making forward-looking statements about future expectations, including relating to the proposed transaction with Elektrofi as outlined on Slide 2. I would also refer you to our SEC filings for a full list of risks and uncertainties.
I will
Read the full article here